Measurement of mucosal conductivity by MII is a potential marker of mucosal integrity restored in infants on acid-suppression therapy

J Pediatr Gastroenterol Nutr. 2011 Jul;53(1):120-3. doi: 10.1097/MPG.0b013e318214c3cc.

Abstract

Esophageal multichannel intraluminal impedance (MII) allows measurement of the conductivity of adjacent contents. During esophageal rest, raw impedance levels may represent mucosal integrity. We assessed the influence of proton pump inhibitors (PPIs) on presumed mucosal integrity by reanalyzing raw MII levels of 21 pH-MII tracings from infants with gastroesophageal reflux (GER) disease before and after esomeprazole treatment. Median (interquartile range) esophageal MII increased during treatment, 938 (652-1304) versus 1885 (1360-2183) Ohm, P < 0.0001. Patients with lower MII levels demonstrated a larger increase on therapy: Spearman r2 = 0.28, P = 0.014. No correlation with standard GER parameters was observed. In conclusion, PPI therapy increases MII levels in infants with symptomatic GER disease.

Publication types

  • Clinical Trial

MeSH terms

  • Anti-Ulcer Agents / therapeutic use
  • Biomarkers
  • Cohort Studies
  • Electric Conductivity*
  • Electrochemical Techniques
  • Esomeprazole / therapeutic use
  • Esophagus / drug effects*
  • Esophagus / physiopathology
  • Gastroesophageal Reflux / diagnosis*
  • Gastroesophageal Reflux / drug therapy*
  • Gastroesophageal Reflux / physiopathology
  • Humans
  • Hydrogen-Ion Concentration
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Mucous Membrane / drug effects*
  • Mucous Membrane / physiopathology
  • Proton Pump Inhibitors / therapeutic use*
  • Severity of Illness Index

Substances

  • Anti-Ulcer Agents
  • Biomarkers
  • Proton Pump Inhibitors
  • Esomeprazole